More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of ...
No. 49 / 2024Zealand Pharma Announces Financial Results for the First Nine Months of 2024Continued strong progress across ...
Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...
News Medical on MSN2d
CKM syndrome leads to elevated cardiovascular disease risk earlier in lifePeople with chronic kidney disease, Type 2 diabetes or both were predicted to have elevated cardiovascular disease (CVD) risk 8 to 28 years sooner than someone without those conditions, according to a ...
Welcome to the GoodRx third-quarter 2024 earnings call. As a reminder, today's conference call is being recorded. I would now ...
DelveInsight's D-Dimer Testing Market Insights report provides the current and forecast market analysis, individual leading D ...
Armed with results from a phase 2 trial, Boehringer Ingelheim has said it will take its obesity drug candidate survodutide into a phase 3 programme later this year. The glucagon/GLP-1 receptor ...
DelveInsight's Respiratory Disease Testing Market Insights report provides the current and forecast market analysis, individual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback